Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors.

Noelia Nebot,H-T Arkenau,Jeffrey R. Infante,Jason Claud Chandler,Andrew Weickhardt,Jason Lickliter,John Sarantopoulos,Michael S. Gordon,Annie St-Pierre,Lihua Tang,Bijoyesh Mookerjee,Stanley W. Carson,Kenneth F. Grossmann

Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors.

2016

Noelia Nebot
H-T Arkenau
Jeffrey R. Infante
Jason Claud Chandler
Andrew Weickhardt
Jason Lickliter
John Sarantopoulos
Michael S. Gordon
Annie St-Pierre
Lihua Tang
Bijoyesh Mookerjee
Stanley W. Carson
Kenneth F. Grossmann

e14119Background: Dabrafenib (DAB) is a BRAF inhibitor approved at a dose of 150 mg twice daily (BID) for treating unresectable or metastatic BRAF V600E/K–mutant melanoma with or without trametinib...

Keywords:

QT interval
Dabrafenib
Cancer research
Mutant
Pathology
Medicine
Trametinib
Melanoma
BRAF V600E
in patient
Oncology
Internal medicine
BRAF inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations